| EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy JG Paez, PA Janne, JC Lee, S Tracy, H Greulich, S Gabriel, P Herman, ... Science 304 (5676), 1497-1500, 2004 | 12121 | 2004 |
| MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ... science 316 (5827), 1039-1043, 2007 | 5522 | 2007 |
| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5491 | 2010 |
| EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib S Kobayashi, TJ Boggon, T Dayaram, PA Jänne, O Kocher, M Meyerson, ... New England Journal of Medicine 352 (8), 786-792, 2005 | 4845 | 2005 |
| The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010 | 4422 | 2010 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4112 | 2013 |
| AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer PA Jänne, JCH Yang, DW Kim, D Planchard, Y Ohe, SS Ramalingam, ... New England Journal of Medicine 372 (18), 1689-1699, 2015 | 2341 | 2015 |
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing M Imielinski, AH Berger, PS Hammerman, B Hernandez, TJ Pugh, ... Cell 150 (6), 1107-1120, 2012 | 2045 | 2012 |
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy … DA Eberhard, BE Johnson, LC Amler, AD Goddard, SL Heldens, ... Journal of clinical oncology 23 (25), 5900-5909, 2005 | 1850 | 2005 |
| Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M KS Thress, CP Paweletz, E Felip, BC Cho, D Stetson, B Dougherty, Z Lai, ... Nature medicine 21 (6), 560-562, 2015 | 1578 | 2015 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1556 | 2012 |
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ... Nature communications 7 (1), 10501, 2016 | 1506 | 2016 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1354 | 2018 |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013 | 1340 | 2013 |
| EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer JP Koivunen, C Mermel, K Zejnullahu, C Murphy, E Lifshits, AJ Holmes, ... Clinical cancer research 14 (13), 4275-4283, 2008 | 1258 | 2008 |
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ... Cancer cell 17 (1), 77-88, 2010 | 1250 | 2010 |
| LKB1 modulates lung cancer differentiation and metastasis H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ... Nature 448 (7155), 807-810, 2007 | 1200 | 2007 |
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ... Nature 462 (7276), 1070-1074, 2009 | 1199 | 2009 |
| The quest to overcome resistance to EGFR-targeted therapies in cancer CR Chong, PA Jänne Nature medicine 19 (11), 1389-1400, 2013 | 1126 | 2013 |
| The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ... Cancer discovery 10 (1), 54-71, 2020 | 1103 | 2020 |
